← ANALYST RATINGS · TIPRANKS
Autolus Therapeutics (AUTL): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $10.00, the highest $10.00, the lowest $10.00. The average is +525.0% from the last price of $1.60.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 → $1.50−25.0% | Hold | −6.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 → $1.50−25.0% | Hold | −6.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | −6.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Hold | −6.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 → $1.50−25.0% | Hold | −6.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Hold | −6.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| Unknown Analyst | Wells Fargo | $5.00 | Buy | +212.5% | Reiterated | 02.10.26on TipRanks Oct 7 00:05 | −4.5%next day +2.1% · 5 days +0.5% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $10.00 | Buy | +525.0% | Reiterated | 02.10.26on TipRanks 13:55 | −4.5%next day +2.1% · 5 days +0.5% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 25.09.26on TipRanks 11:07 | −3.4%next day +1.0% · 5 days −3.8% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $10.00 | Buy | +525.0% | Reiterated | 21.09.26on TipRanks 13:55 | −1.6%next day +4.7% · 5 days −3.1% | ↗ |
| Rajan Sharma★★★★★★★★★★#5820 · hits 52% · avg +1.9% | Goldman Sachs | $5.40 → $5.80+7.4% | Buy | +262.5% | Assigned | 11.08.26on TipRanks Aug 12 03:35 | +12.9%next day −9.3% · 5 days −1.3% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $10.00 | Buy | +525.0% | Reiterated | 10.06.26on TipRanks 12:30 | +2.9%next day +3.7% · 5 days +1.2% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | $10.00 → $8.00−20.0% | Buy | +400.0% | Reiterated | 13.01.26on TipRanks 08:38 | −8.5%next day +4.1% · 5 days +8.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Autolus Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 02.10.26: target $7.70 at a price of $1.85 (+316.2%); now: $7.70 at $1.60 (+381.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 1 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.16 (from $-0.22 to $-0.10). Last quarter: $-0.15.
Sales
Next quarter’s sales estimate — $40M (from $37M to $46M). Last quarter: $46M.
Best top-analyst consensus in the sector · Healthcare
About Autolus Therapeutics
- CEO: Christian Martin Itin
- Employees: 752
- The MediaWorks, London, GL, W12 7FP, GB
- www.autolus.com
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Data from the stock’s TipRanks forecast page, read 38 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗